Violeta Railean

Violeta Railean

Auto-generated profile, based on publicly available information

Violeta Railean

BioISI - Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande C8 bdg, 1749-016, Lisboa, Portugal

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2022 in The FASEB Journal
Verified
Journal Article
Open access
SJSungwoo Jo
Sungwoo Jo
RCRaquel Centeio
Raquel Centeio
JPJinhong Park
Jinhong Park
JOJiraporn Ousingsawat
Jiraporn Ousingsawat
DJDongkyu Jeon
Dongkyu Jeon
KKKarl Kunzelmann
Karl Kunzelmann
The solute carrier 26 family member A9 (SLC26A9) is an epithelial anion transporter that is assumed to contribute to airway chloride secretion and surface hydration. Whether SLC26A9 or CFTR is responsible for airway Cl − transport under basal conditions is still unclear, due to the lack of a specific inhibitor for SLC26A9. In the present study, we report a novel potent and specific inhibitor for SLC26A9, identified by screening of a drug‐like molecule library and subsequent chemical modifications. The most potent compound S9‐A13 inhibited SLC26A9 with an IC 50 of 90.9 ± 13.4 nM. S9‐A13 did not inhibit other members of the SLC26 family and had no effects on Cl − channels such as CFTR, TMEM16A, or VRAC. S9‐A13 inhibited SLC26A9 Cl − currents in cells that lack expression of CFTR. It also inhibited proton secretion by HGT‐1 human gastric cells. In contrast, S9‐A13 had minimal effects on ion transport in human airway epithelia and mouse trachea, despite clear expression of SLC26A9 in the apical membrane of ciliated cells. In both tissues, basal and stimulated Cl − secretion was due to CFTR, while acidification of airway surface liquid by S9‐A13 suggests a role of SLC26A9 for airway bicarbonate secretion.

6 February 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
Cláudia S. RodriguesCláudia S. Rodrigues
Cláudia S. Rodrigues
VRVioleta Railean
Violeta Railean
SRSofia S Ramalho
Sofia S Ramalho
Carlos FarinhaCarlos Farinha
Carlos Farinha
IPInes Pankonien
Ines Pankonien
MAMargarida Amaral
Margarida Amaral
Elucidating the molecular and cellular effects caused by CFTR variants is crucial to understand Cystic Fibrosis (CF) disease pathophysiology, but also to predict disease severity, to provide genetic counselling, and to determine the most adequate therapeutic strategy for people with CF (pwCF). While the current CFTR modulator drugs (CFTRm) are approved mainly for pwCF with the most prevalent variant, p.Phe508del, pwCF carrying rare and/or uncharacterized CFTR variants are not eligible. However, previous studies have shown that such rare variants can be rescued by the approved CFTRm, suggesting clinical benefit for those pwCF. Here, we characterized the rare and non-eligible p.Ile148Asn CFTR variant found in Portuguese pwCF, regarding CFTR processing, traffic and function, and response to existing CFTRm. We used the forskolin-induced swelling (FIS) assay in intestinal organoids (IOs) from 2 CF individuals carrying p.Ile148Asn in heterozygosity with p.Phe508del and p.Gly542Ter, respectively. Additionally, a Cystic Fibrosis Bronchial Epithelial (CFBE) cell line expressing p.Ile148Asn-CFTR was generated to study the molecular defect of this variant individually. Our results show that p.Ile148Asn is a CF-causing variant, impairing both CFTR plasma membrane (PM) traffic and function, albeit partially. Moreover, p.Ile148Asn-CFTR can be rescued by approved CFTRm in CFBE cells and IOs, suggesting potential clinical benefit for these individuals. The work emphasizes the importance of testing CFTRm for rare variants not included in the drug label. It also shows that the 'theranostic' approach using IOs from pwCF, which captures the genetic background of each individual, complements theratyping in cell lines that focuses only on CFTR variants.

15 July 2025 in Respiratory Medicine
Verified
Journal Article
Closed access
JPJoana Pacheco
Joana Pacheco
LALeonor Almeida
Leonor Almeida
RBRita Boaventura
Rita Boaventura
APAna Luisa Pereira
Ana Luisa Pereira
Cláudia S. RodriguesCláudia S. Rodrigues
Cláudia S. Rodrigues
AAAdelina Amorim
Adelina Amorim